시장보고서

상품코드

1986797

COPD 및 천식 치료 기기 시장 보고서 : 제품별, 적응증별, 유통 채널별, 지역별(2026-2034년)

COPD and Asthma Devices Market Report by Product (Inhalers, Nebulizers), Indication (Asthma, COPD), Distribution Channel (Retail Pharmacies, Hospitals, Online Pharmacies), and Region 2026-2034

발행일: 2026년 03월 | 리서치사: 구분자

IMARC | 페이지 정보: 영문 135 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 COPD 및 천식 치료용 기기 시장 규모는 2025년에 499억 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 725억 달러에 달하고, 2026년부터 2034년까지 CAGR 4.24%로 성장할 것으로 예측했습니다. 시장 성장은 주로 실시간 모니터링 기능을 갖춘 스마트 흡입기의 지속적인 기술 발전, 호흡기질환의 유병률 증가, 보다 정확한 약물전달을 위한 맞춤형 치료에 대한 관심 증가, 의료 서비스 접근성 향상에 따른 신흥 시장에서의 수요 증가에 의해 주도되고 있습니다.

만성폐쇄성폐질환(COPD)은 폐의 공기 흐름을 방해하는 염증성 질환입니다. 초기 증상으로는 호흡곤란, 천명음, 흉부 압박감, 가래를 동반하거나 동반하지 않는 만성 기침, 잦은 감기, 인후통 등이 있습니다. 한편, 기관지 천식이라고도 불리는 천식은 폐의 기도에 영향을 미치는 호흡기질환입니다. 증상으로는 호흡곤란, 가슴 압박감, 수면 장애, 기침과 천명음 발작 등이 있습니다. 이러한 호흡기질환은 흡입제를 투여하는 데 도움이 되는 다양한 기기를 사용하여 치료합니다. COPD 및 천식용 기기(폐 약물전달 기기라고도 함)는 호흡기질환의 상시 치료 및 응급 치료로 사용되고 있습니다. 그 결과, 전 세계적으로 큰 주목을 받고 있습니다.

COPD 및 천식용 의료기기 시장 동향:

맞춤형 치료에 대한 관심 증가

맞춤형 의료로의 전환은 COPD 및 천식 기기 시장 점유율에 큰 영향을 미치고 있습니다. 각 제조사들이 환자 개개인의 니즈에 맞는 솔루션 제공에 집중하고 있기 때문입니다. 환자의 편안함과 치료의 정확성을 높이기 위해 설계된 맞춤형 흡입기 및 분무기가 점점 더 많은 관심을 받고 있습니다. 개별화된 투약 시스템은 정확한 약물전달을 보장하고, 부작용을 최소화하며, 전체 치료 효과를 높입니다. 또한, 호흡기질환에 관여하는 특정 분자 경로를 표적으로 삼는 생물학적 제제의 등장으로 전문적이고 정교한 투약 기기의 사용이 촉진되고 있습니다. 이러한 개별화된 접근 방식을 통해 만성 호흡기질환을 보다 효과적으로 관리할 수 있습니다. 이러한 맞춤형 솔루션에 대한 수요가 증가함에 따라 시장은 확대될 것으로 예상되며, 호흡기 치료에서 개인화된 헬스케어의 광범위한 추세를 반영할 것으로 보입니다.

흡입기 설계의 기술적 진보

최신 COPD 및 천식 치료 기기 시장 동향에 따르면, 흡입기 기술의 지속적인 혁신이 시장을 주도하고 있으며, 이러한 호흡기질환의 관리를 변화시키고 있습니다. 센서와 블루투스 연결 기능을 갖춘 스마트 흡입기는 약물의 사용 상황과 복약 순응도를 실시간으로 모니터링할 수 있습니다. 이러한 발전을 통해 환자와 의료진은 흡입 패턴을 추적하고 치료를 조정하여 질병 관리를 개선할 수 있습니다. 모바일 앱 통합을 통해 알림 기능, 증상 추적, 임상의와의 데이터 공유를 제공함으로써 이를 더욱 지원합니다. 디지털 헬스 솔루션의 보급이 확대됨에 따라 스마트 흡입기에 대한 수요가 증가하고 있으며, 이는 COPD 및 천식용 기기 시장의 성장에 기여하고 있습니다.

신흥 시장에서의 수요 증가

COPD 및 천식 치료 기기 시장 규모는 신흥 경제국에서 수요가 크게 증가하고 있습니다. 급속한 도시화, 대기오염 수준 악화, 흡연율 증가 등의 요인이 아시아태평양, 라틴아메리카, 중동 등의 지역에서 호흡기질환의 유병률 증가에 기여하고 있습니다. 15세 이상 흡연자는 약 11억 명에 달하며, 이 중 80%가 중저소득국가(LMICs)에 거주하고 있습니다. 특히 청소년층의 흡연율 증가는 보다 엄격한 규제가 이루어지지 않는다면 건강 및 경제적 부담을 증가시킬 수 있습니다. 이들 지역의 정부와 의료시스템은 COPD와 천식으로 인해 증가하는 부담을 해결하기 위해 더 나은 진단 도구와 치료 장비에 대한 투자를 진행하고 있습니다. 또한, 의료 서비스 접근성 향상과 휴대용 흡입기 및 분무기의 보급 확대는 이들 지역의 시장 성장을 촉진하고 있으며, 신흥 시장은 향후 시장 확대를 위한 중요한 거점이 될 것으로 보입니다.

The global COPD and asthma devices market size reached USD 49.9 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 72.5 Billion by 2034, exhibiting a growth rate (CAGR) of 4.24% during 2026-2034. The market growth is primarily driven by continual technological advancements in smart inhalers with real-time monitoring capabilities, growing prevalence of respiratory conditions, an enhanced emphasis on personalized treatment options for more accurate drug delivery and increasing demand in emerging markets due to improved healthcare access.

Chronic obstructive pulmonary disease (COPD) is an inflammatory disease that leads to obstructed airflow from the lungs. Its early symptoms include shortness of breath, wheezing, chest tightness, chronic cough with or without mucus, frequent cold, and throat soreness. On the other hand, asthma, also known as bronchial asthma, is a respiratory disorder that affects the airways in the lungs. Its symptoms are shortness of breath, chest tightness, trouble sleeping, and coughing or wheezing attacks. These respiratory diseases are treated using various devices that help deliver inhaled medication. COPD and asthma devices, also known as pulmonary drug delivery devices, are used as permanent treatment or rescue therapy for respiratory diseases. As a result, they are gaining immense traction across the globe.

COPD AND ASTHMA DEVICES MARKET TRENDS:

Increased Focus on Personalized Treatment Options

The shift towards personalized medicine is causing a substantial effect on the COPD and asthma devices market share, as manufacturers focus on offering solutions tailored to individual patient requirements. Customizable inhalers and nebulizers are becoming more prominent, designed to enhance patient comfort and treatment precision. Personalized dosing systems ensure accurate medication delivery, minimizing side effects and augmenting overall treatment effectiveness. Additionally, the rise of biologic therapies targeting specific molecular pathways involved in respiratory conditions, is encouraging the use of specialized and advanced delivery devices. This personalized approach allows for more effective management of chronic respiratory diseases. As demand for these customized solutions grows, the market is expected to expand, reflecting a broader trend towards individualized healthcare in respiratory treatment.

Technological Advancements in Inhaler Design

Ongoing innovations in inhaler technology are leading the market according to the latest COPD and asthma devices market trends, transforming the management of these respiratory conditions. Smart inhalers, equipped with sensors and Bluetooth connectivity, enable real-time monitoring of medication usage and adherence. This advancement allows patients and healthcare providers to track inhalation patterns and adjust treatments for improved disease control. The integration of mobile apps further supports this by offering reminders, symptom tracking, and data sharing with clinicians. As digital health solutions gain wider adoption, the demand for smart inhalers is rising, which is contributing to the overall growth of the COPD and asthma devices market.

Rising Demand in Emerging Markets

The COPD and asthma devices market size is witnessing strong growth in demand from emerging economies. Factors such as rapid urbanization, rising air pollution levels, and higher smoking rates are contributing to the prevalence of respiratory conditions in regions such as Asia-Pacific, Latin America, and the Middle East. Around 1.1 billion individuals over the age of 15 and over smoke, with 80% residing in low and middle income countries (LMICs). Rising smoking rates, especially among adolescents, pose growing health and economic burdens without stricter controls. Governments and healthcare systems in these regions are investing in better diagnostic tools and treatment devices to address the growing burden of COPD and asthma. Additionally, improved access to healthcare and the increasing adoption of portable inhalers and nebulizers are augmenting market growth in these regions, making emerging markets key centres for future expansion.

COPD AND ASTHMA DEVICES MARKET SEGMENTATION:

Breakup by Product:

Inhalers
- Drug Powdered Inhalers (DPIs)
- Metered Dose Inhalers (MDIs)
- Soft Mist Inhalers
Nebulizers
- Compressor Nebulizers
- Ultrasonic Nebulizers
- Mesh Nebulizers

Breakup by Indication:

Asthma
COPD

Breakup by Distribution Channel:

Retail Pharmacies
Hospitals
Online Pharmacies

Breakup by Region:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global COPD and asthma devices market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:

Adherium Limited
Aerogen Ltd
AptarGroup, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc.
Cipla Limited
GF Health Products, Inc
GSK plc
PARI Respiratory Equipment, Inc.
ResMed
Teva Pharmaceuticals USA, Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global COPD and asthma devices market in 2025?

2. What is the expected growth rate of the global COPD and asthma devices market during 2026-2034?

3. What are the key factors driving the global COPD and asthma devices market?

4. What has been the impact of COVID-19 on the global COPD and asthma devices market?

5. What is the breakup of the global COPD and asthma devices market based on the product?

6. What is the breakup of the global COPD and asthma devices market based on the indication?

7. What is the breakup of the global COPD and asthma devices market based on distribution channel?

8. What are the key regions in the global COPD and asthma devices market?

9. Who are the key players/companies in the global COPD and asthma devices market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global COPD and Asthma Devices Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product

6.1 Inhalers
- 6.1.1 Market Trends
- 6.1.2 Key Segments
  - 6.1.2.1 Drug Powdered Inhalers (DPIs)
  - 6.1.2.2 Metered Dose Inhalers (MDIs)
  - 6.1.2.3 Soft Mist Inhalers
- 6.1.3 Market Forecast
6.2 Nebulizers
- 6.2.1 Market Trends
- 6.2.2 Key Segments
  - 6.2.2.1 Compressor Nebulizers
  - 6.2.2.2 Ultrasonic Nebulizers
  - 6.2.2.3 Mesh Nebulizers
- 6.2.3 Market Forecast

7 Market Breakup by Indication

7.1 Asthma
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 COPD
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

8.1 Retail Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Hospitals
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Online Pharmacies
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Adherium Limited
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
- 14.3.2 Aerogen Ltd
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 AptarGroup, Inc.
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 Boehringer Ingelheim Pharmaceuticals, Inc.
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
- 14.3.5 Cipla Limited
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
  - 14.3.5.4 SWOT Analysis
- 14.3.6 GF Health Products, Inc
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
  - 14.3.6.4 SWOT Analysis
- 14.3.7 GSK plc
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
  - 14.3.7.4 SWOT Analysis
- 14.3.8 PARI Respiratory Equipment, Inc.
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
- 14.3.9 ResMed
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials
  - 14.3.9.4 SWOT Analysis
- 14.3.10 Teva Pharmaceuticals USA, Inc.
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 Financials
  - 14.3.10.4 SWOT Analysis